BlackRock, Inc. 13D and 13G filings for 4D Molecular Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-04-17 09:35 am Sale | 2025-03-31 | 13G | 4D Molecular Therapeutics, Inc. FDMT | BlackRock Inc. BLK | 3,615,316 7.800% | -1,349,703 (-27.18%) | Filing |
| 2024-12-06 4:28 pm Purchase | 2024-11-30 | 13G | 4D Molecular Therapeutics, Inc. FDMT | BlackRock Inc. BLK | 4,965,019 10.700% | 96,230 (+1.98%) | Filing |
| 2024-11-08 2:17 pm Unchanged | 2024-09-30 | 13G | 4D Molecular Therapeutics, Inc. FDMT | BlackRock Inc. BLK | 4,868,789 9.400% | 0 (Unchanged) | Filing |
| 2024-10-21 4:11 pm Purchase | 2024-09-30 | 13G | 4D Molecular Therapeutics, Inc. FDMT | BlackRock Inc. BLK | 4,868,789 9.400% | 1,404,202 (+40.53%) | Filing |
| 2024-01-25 4:59 pm Purchase | 2023-12-31 | 13G | 4D Molecular Therapeutics, Inc. FDMT | BlackRock Inc. BLK | 3,464,587 8.100% | 955,955 (+38.11%) | Filing |
| 2023-01-31 1:58 pm Purchase | 2022-12-31 | 13G | 4D Molecular Therapeutics, Inc. FDMT | BlackRock Inc. BLK | 2,508,632 7.700% | 420,950 (+20.16%) | Filing |
| 2022-02-04 4:12 pm Purchase | 2021-12-31 | 13G | 4D Molecular Therapeutics, Inc. FDMT | BlackRock Inc. BLK | 2,087,682 6.500% | 2,087,682 (New Position) | Filing |